Navigation Links
Mirati Therapeutics Reports Second Quarter 2014 Financial Results and Provides Business Update
Date:8/8/2014

same period in 2013. Research and development expenses for the six months ended June 30, 2014 were $12.4 million, compared to $10.0 million for the same period in 2013. The Company's research and development expenses during the second quarter and six months ended June 30, 2014 primarily consisted of costs to advance the clinical development of its three oncology programs, MGCD265, MGCD516 and mocetinostat. General and administrative expenses for the second quarter of 2014 were $2.9 million, compared to $2.4 million for the same period in 2013. General and administrative expenses for the six months ended June 30, 2014 were $5.3 million, compared to $4.9 million for the same period in 2013.

Other expense, net for the second quarter of 2014 was $0.9 million compared to $1.1 million for the same period in 2013. Other expense, net for the six months ended June 30, 2014 was $6.6 million compared to other income of $2.7 million for the same period in 2013. Other income or expense, net is comprised primarily of gains or losses arising from the change in fair value of our warrant liability.

Net loss and comprehensive loss for the second quarter was $11.0 million, or $0.82 per share, compared to net loss and comprehensive loss of $8.0 million, or $0.80 per share for the same period in 2013. Net loss and comprehensive loss for the six months ended June 30, 2014 was $24.7 million, or $1.83 per share, compared to net loss and comprehensive loss of $12.2 million, or $1.23 per share for the same period in 2013.

About Mirati Therapeutics
Mirati Therapeutics is a targeted oncology company developing an advanced pipeline of breakthrough medicines for precisely defined patient populations. Mirati's approach combines the three most important factors in oncology drug development - drug candidates with complementary and compelling targets, creative and agile clinical development, and a highly accomplished precision medicine leadership team. The Mirati tea
'/>"/>

SOURCE Mirati Therapeutics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Mirati Presents Clinical Response Results of Mocetinostat in Combination with Azacitidine as a Treatment for MDS
2. Updated Presentation Time: Mirati Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
3. Mirati Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
4. Mirati Therapeutics Reports Third Quarter 2013 Financial Results
5. Mirati Therapeutics Prices Public Offering Of Common Stock
6. Mast Therapeutics To Present At The Canaccord Genuity 34th Annual Growth Conference On August 14th
7. Orexigen Therapeutics Reports Corporate and Financial Results for the Second Quarter Ended June 30, 2014
8. PTC Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update
9. Pivotal Therapeutics To Explore Potential Commercial Partnership Opportunities in China
10. Relmada Therapeutics, Inc. Completes Name Change and Announces New Ticker
11. PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Ill. , Dec. 19, 2014   Hospira, ... leading provider of injectable drugs and infusion technologies, today ... Morgan 33rd Annual Healthcare Conference on Wednesday, Jan. 14, ... presentation is scheduled to begin at 10:30 a.m. Pacific ... available to all interested parties through a live audiocast ...
(Date:12/19/2014)... CARDIFF-BY-THE-SEA, Calif. , Dec. 19, ... SRNE ;  Sorrento), an oncology company developing new ... Inc., a privately-held immuno-oncology company developing proprietary Neukoplast ... based therapy, announced today that the companies have ... next generation CAR-TNK™ (pronounced as "Car-Tank") immunotherapies for ...
(Date:12/19/2014)... LOS ALTOS, Calif. , Dec. 18, 2014 ... of a new generation of equipment for the ... today the release of the new Luminary™ Profiler, ... highly accurate light-based measurement in a cost-effective, portable ... to meet the specific needs of the cannabis ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2
... October 12, 2011 Leading health ... titles freely available through UN developing world research access ... scientific, technical and medical information products and services, today ... books to Research4Life , a public-private partnership working ...
... Mass., Oct. 11, 2011 Boston Scientific Corporation (NYSE: ... results for the third quarter ended September 30, 2011 on ... call will be hosted by Hank Kucheman, who becomes Boston ... Executive Vice President and Chief Financial Officer. A ...
Cached Medicine Technology:Elsevier Offers 950 New Health Titles to Research4Life 2Elsevier Offers 950 New Health Titles to Research4Life 3Boston Scientific To Webcast Conference Call Discussing Third Quarter 2011 Financial Results 2
(Date:12/21/2014)... AZ (PRWEB) December 21, 2014 Parker ... range of heating, cooling, plumbing and other similar home ... in 2014 with regard to its expert contracting services. ... industry leader that has been serving Arizona for well ... in providing the absolute best in quality customer service ...
(Date:12/21/2014)... CannabisClassifieds.com celebrates marijuana’s new legal place at the ... its kind, the site has provided its faithful users with ... running. It uniquely combines the benefits of platforms like ... to the masses. Assuring the potent herb’s followers it’s ... public approval. , Shane Chattin, Owner of Cannabis ...
(Date:12/20/2014)... MissyDress, a distinguished special dress supplier, has just ... has drastically cut prices to all its prom dresses ... 30, 2015. Many of the hottest styles are sold ... dresses, and more. , A spokesman for MissyDress says, ... A-line princess prom dresses or sweetheart chiffon prom dresses, ...
(Date:12/20/2014)... The print component of Healthy Aging ... of approximately 160,000 copies and an estimated readership of ... vast social media strategy and across a network of ... digital version of the campaign, click here . ... the ladies of CTV’s The Social. Lainey Lui, ...
(Date:12/20/2014)... 20, 2014 As Risperdal lawsuits ... in U.S. courts, Bernstein Liebhard LLP notes the ... children treated with the medication may experience elevated ... development and lactation. The study, which appears in ... adolescents who began treatment with risperidone, an antipsychotic ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 2Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 3Health News:CannabisClassifieds.com Maintains its “Craigslist for Cannabis” Standing with Website Re-launch 2Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4
... , Republican Congressman Slated to Oppose President Obama,s ... Insurance Campaign Contributions , , WASHINGTON, Sept. ... questions about Rep. Charles Boustany (R-La.) and the expected opposing remarks ... to a joint session of Congress on health care reform. , ...
... , , , WASHINGTON, ... the National Governors Association will speak at a National Press Club luncheon ... Rx for Health Reform: Affordable, Accessible, Accountable which looks ... health care reform. , , (Logo: ...
... prevent sudden cardiac death, researchers recommend electrocardiograms , WEDNESDAY, ... tested for heart abnormalities to prevent sudden cardiac death ... Sudden cardiac death is the leading cause of death ... it is, as figures vary and mandatory reporting does ...
... , ARMONK, N.Y., Sept. 9 Reducing the risk of ... among the top concerns of the pharmaceutical and life sciences industries today, ... IBM ) study. More than 50 percent of executives polled ... emergencies because of lapses in their supply chain. , , ...
... , , LEWISTON, Maine and THOUSAND ... sponsor of The Dempsey Challenge: A Journey for Hope, a cycling and ... supports The Patrick Dempsey Center for Cancer Hope & Healing at Central ... an opportunity to expand Amgen,s Breakaway from Cancer ((R)) ...
... , , FRANKLIN, Mass., Sept. 9 ... diabetes management company developing the needle-free Symphony(TM) tCGM System ... system and the Prelude(TM) SkinPrep System for transdermal drug ... presentation at the Rodman & Renshaw 2009 Annual Global ...
Cached Medicine News:Health News:Rep. Boustany Hauled in $1.25 Million From Health and Insurance Industry 2Health News:NGA Chair, Vermont Governor Douglas to Speak on States' Role in Health Care Reform at the National Press Club on September 17 2Health News:Testing Young Athletes for Heart Defects May Save Lives 2Health News:IBM Study Reveals Drug Companies Struggle to Improve Supply Chain to Battle Counterfeiting, Safety Concerns and Global Complexity 2Health News:IBM Study Reveals Drug Companies Struggle to Improve Supply Chain to Battle Counterfeiting, Safety Concerns and Global Complexity 3Health News:IBM Study Reveals Drug Companies Struggle to Improve Supply Chain to Battle Counterfeiting, Safety Concerns and Global Complexity 4Health News:Amgen Named Presenting Sponsor of The Dempsey Challenge: A Journey For Hope 2Health News:Amgen Named Presenting Sponsor of The Dempsey Challenge: A Journey For Hope 3Health News:Amgen Named Presenting Sponsor of The Dempsey Challenge: A Journey For Hope 4Health News:Echo Therapeutics Announces New Presentation Time at Rodman & Renshaw 2009 Annual Global Investment Conference 2
... CMGS-1 Color Mini-Ganzfeld Stimulator is an advanced, ... integrated with your existing LKC system or ... visual electrodiagnostic test systems. Using LKCs ... smallest commercial Ganzfeld to meet ISCEV (International ...
... UTAS-E 3000 is the most advanced ... and accurate measurements of retinal and ... easy-to-use software available drives this powerful ... as adjustable contrast pattern stimulation, rapid ...
... CC cages are designed to facilitate an ... approach. These are interbody cages allowing radicular ... interve rtebral space and of the foramina, ... are particularly indicated for major lumbar instabilities.,CC ...
... SHELLGEL is a sterile nonpyrogenic, transparent ... SHELLGEL contains 12 mg/mL of high molecular ... hyaluronate dissolved in physiological saline. In the ... is 105,000 cps (105 Pa s) at ...
Medicine Products: